In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. (VRTX) has taken over the #152 spot from Humana Inc. (HUM), according to ETF Channel. Below is a chart of Vertex Pharmaceuticals, Inc. versus Humana Inc. plotting their respective rank within the S&P 500 over time (VRTX plotted in blue; HUM plotted in green):In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages. Investors often interpret analyst opinions from different angles — a popular analyst pick could mean that many sharp minds individually came to the same bullish conclusion, and therefore the stock should do well... but it could also mean that if the company makes any slight stumble, that would come as a negative surprise and cause a downward impact on the stock. From the other direction, when companies have a low rank among analysts, it isn't necessarily the case that investors should conclude that the stock will perform poorly. It can mean that of course, but: a bullish investor who can make a case for a positive future catalyst could also take the contrarian angle and recognize that there is lots of room for upside since the stock is presently so out of favor. For these reasons, we at ETF Channel find value to putting together these rankings, because both the top and the bottom ends of the lists can often make for some interesting stock picking ideas for further research. Below is a three month price history chart comparing the stock performance of VRTX vs. HUM:
According to the ETF Finder at ETF Channel, VRTX and HUM collectively make up 1.63% of the Health Care Select Sector SPDR Fund ETF (XLV) which is trading up by about 1.1% on the day Tuesday.
VRTX is currently trading off about 1.5%, while HUM is up about 0.2% midday Tuesday.